Immunotherapy of metastatic breast cancer: phase I trail of reduced-intensity allogeneic hematopoietic stem cell transplantation with Th2/Tc2 T-cell exchange.
Hardy
Nancy M
NM
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. hardyn@mail.nih.gov
Fowler
Daniel H
DH
Bishop
Michael R
MR
D000293:Adolescent; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D020350:Graft vs Tumor Effect / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D007231:Infant, Newborn; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D019172:Transplantation Conditioning / Q000379:methods*; D014181:Transplantation Immunology; D014184:Transplantation, Homologous